Diagnosing and treating hematopoietic cancers

• US 7,723,055 B2
• Filed: 10/18/2007
• Issued: 05/25/2010
• Est. Priority Date: 11/21/2002
• Status: Expired due to Fees

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Pihan, German, Jones, Stephen N., Liang, Huiling
• Primary Examiner(s): Falk; Anne-Marie
• Assistant Examiner(s): Sgagias; Magdalene K
• Application Number:
  US11/874,703
• Publication Number:
  US 20080090245A1
• Time in Patent Office: 950 Days
• Field of Search: 435/7.23, 435/7.2, 435/4
• US Class Current: 435/7.23
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

Described herein are methods and compositions comprising Wnt5a for the diagnosis and treatment of hematopoietic cancers, and methods of identifying therapeutic compounds for the treatment of hematopoietic cancers.

Claims

1. A method of determining whether a mammal has acute lymphoblastic leukemias (ALL) or acute myeloid leukemias (AML), the method comprising:

providing a biological sample comprising a test cell from the mammal, wherein the test cell is a lymphoid cell or a myeloid cell; and

determining the level of Wnt5a mRNA within the test cell, wherein a significantly reduced level of Wnt5a mRNA in the test cell, relative to that in a non-cancerous control lymphoid or myeloid cell of the same type as the test cell, indicates that the mammal has ALL or AML.

2. The method of claim 1, wherein the mammal is a human patient.

3. The method of claim 1, wherein the acute leukemia is acute myeloid leukemia (AML).

4. The method of claim 1, wherein the acute leukemia is acute lymphoblast leukemia (ALL).

5. The method of claim 1, wherein both the test cell and the control cell are B cells, T cells, eosinophils, basophils, erythrocytes, neutrophils, granulocytes, or monocytes.

6. The method of claim 1, further comprising culturing one or both of the test cell and the control cell before determining the level of Wnt5a mRNA.

7. The method of claim 1, wherein determining the level of Wnt5a mRNA comprises exposing mRNA isolated from the test cell to a Wnt5a-specific nucleic acid primer or probe.

8. The method of claim 1, wherein both the test cell and the control cell are human cells.

9. The method of claim 1, wherein both the test cell and the control cell are lymphoid cells, and a reduced level of Wnt5a mRNA in the test cell, relative to that in the control cell, indicates that the mammals has ALL.

10. The method of claim 1, wherein both the test cell and the control cell are myeloid cells, and a reduced level of Wnt5a mRNA in the test cell, relative to that in the control cell, indicates that the mammal has AML.